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Objectives: According to the GOLD-2011 report pharmacotherapy in stable COPD 
is used to reduce the symptoms, frequency and severity of exacerbations, improve 
health status and exercise tolerance. MethOds: Our aim was to assess the list of 
medicines, which are available in Ukraine for COPD treatment. We compared the 
medications included in the State Formulary of Ukraine with the dosage forms and 
typical doses of COPD medications list provided by GOLD-2011. Also we calculated 
annual course costs for each drug in different dosage forms. The annual course was 
considered as amount of medicine for 365 days in appropriate for COPD basis dosing. 
Information about the medicine prices was obtained from the ukrainian electronic 
pricing database “MORION”. The EUR/UAH exchange rate was 1 EUR = 10.53 UAH 
(20.06.2013) Results: The State Formulary of Ukraine (SFU) contains 19 medicines 
for INN provided by GOLD-2011: 5 INN are in metered dose inhalers (MDI), 5 - in 
dry powder inhalers (DPI), 1 - in smart mist inhaler (SMI), 5 solutions for nebulizer 
and 3 - in tablets. Salbutamol, salmeterol, indacaterol, fluticasone, beclomethasone 
in DPI are not included in the list of SFU, formoterol in MDI and aminophylline, 
prednisone in tablets are not included in this list as well. The most expensive drug 
is tiotropium with annual costs 604.46 EUR for SMI and 533.81 EUR for DPI. The 
annual costs of salmeterol in MDI and formoterol in DPI are 318.55 and 277.30, 
respectively. The cheapest medicine is salbutamol in MDI with 22.13 EUR annually 
but annual costs of salbutamol solution for nebulizer amount 464.48 EUR per year 
per patient. cOnclusiOns: The State Formulary of Ukraine should be reached by 
medicines for COPD management recommended by GOLD. Annual COPD basis costs 
are depending not only from kind of medicine but from it dosage forms as well.
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Objectives: Inhaled corticosteroids in fixed combination with long-acting B2-
agonists could prevent and reduce chronic obstructive pulmonary disease (COPD) 
exacerbations. The aim of this analysis is to compare clinical consequences and direct 
health care costs related to treatment with budesonide/formoterol and fluticasone/
salmeterol for COPD considering the Italian National Health Service (INHS) perspec-
tive. MethOds: Effectiveness data by the PATHOS study, a population-based, retro-
spective, observational registry study conducted in Sweden, in terms of reduction in 
COPD hospitalizations and COPD-related emergency departments (ED) visits were 
considered in order to estimate the differences in resource consumption between 
patients treated with budesonide/formoterol versus fluticasone/salmeterol. Base case 
considers the dosages of the 2 drugs from the PATHOS study, the cost of drugs in 
charge to INHS, COPD hospitalizations costs from Italian real world data and Italian 
national tariffs for COPD-related ED visits. Results: The real world study PATHOS 
demonstrated a significant reduction in COPD hospitalizations and COPD-related ED 
visits with budesonide/formoterol versus fluticasone/salmeterol (-29.1% and -21%, 
respectively); average dosages reported were 568 mcg/day for budesonide/formoterol 
(as budesonide dosage) and 783 mcg/day for fluticasone/salmeterol (as fluticasone 
dosage). In the base case, the treatment for 1 year of 100 patients with budesonide/
formoterol lead to a saving of 43.892€ (21.859€ for drugs, 21.864€ for COPD hospitaliza-
tions and 169€ for COPD-related ED visits) corresponding to -25.2% compared with 
fluticasone/salmeterol treatment. In the most conservative sensitivity analysis which 
consider the DDD dosages for the 2 drugs and COPD hospitalizations and COPD-
related ED visits costs from national tariffs, the treatment for 1 year of 100 patients 
with budesonide/formoterol lead to a saving of 15.523€ (5.754€ for drugs, 9.600€ for 
COPD hospitalizations and 169€ for COPD-related ED visits) corresponding to -12.5% 
compared with fluticasone/salmeterol treatment. cOnclusiOns: Treatment with 
budesonide/formoterol compared to fluticasone/salmeterol could lead to a reduction 
in direct health care costs with relevant improvement in clinical outcomes.
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Objectives: To re-evaluate the economic consequences of parenteral glutamine 
supplementation (PGS) in light of the recent metaanalysis confirming that PGS at a 
dose > 0,20 g/kg body weight per day in intensive care unit (ICU) patients is associ-
ated with reduced mortality, infection rate (IR) and length of stay (LOS). MethOds: 
A simulation model was updated with the new meta-analysis data and clinical 
inputs for the control group from Italian ICU population reported in “Progetto 
Margherita”. Costs are evaluated from the perspective of the Italian hospital and 
derive from official sources. Sensitivity analyses are undertaken to test results’ 
reliability Results: PGS is predicted to reduce mortality rates (-29.0%), IR (-21.2%) 
and overall LOS (-1.07 days/patient), yielding a saving of € 1,047 per patient treated. 
Treatment costs are completely offset by the reduction in hospital stay costs and 
antibiotic costs. Probabilistic sensitivity analysis indicates PGS strategy as dominant 
in more than 90% of cases. cOnclusiOns: Also with contemporary comparative 
efficacy data is PGS in ICU patients expected to be effective in improving outcomes 
and containing costs in Italian hospitals providing intensive care.
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Objectives: To estimate the cost-effectiveness of a novel LAMA, glycopyrronium 
(Seebri® Breezhaler), compared with tiotropium (Spiriva®) in COPD patients from a 
Swedish societal perspective. MethOds: A probabilistic Markov model was utilized to 
Heckman two-step selection model was used. The EQ-5D index score was categorized 
into categories with 0.1 gradations. Marginal effects (ME) were estimated to quantify 
the marginal changes in costs corresponding to, for instance, 0.1 increments in the 
EQ-5D index score, or the presence of asthma or asthma treatment. All costs were 
adjusted to 2003 dollars. Results: The EQ-5D index score was a significant predic-
tor of health care costs in all models, as were asthma, asthma treatment and other 
covariates (p< 0.01). The Heckman model suggested a significant positive spending 
bias (p< 0.01). For the 3 groups considered--non-asthma, asthma and asthma with 
treatment--the mean EQ-5D index scores were 0.848, 0.755 and 0.706, respectively. 
The actual mean costs were $2,355, $4,284 and $5,577, respectively. The predicted 
mean costs using Heckman model were $2,673, $4,431 and $5,618, respectively. On 
average, a 0.1 unit improvement in EQ-5D score was associated with $502 cost reduc-
tion in asthma and $693 cost reduction if asthma patients had treatment (p< 0.01). 
However, after adjusting for positive spending bias, the cost reduction was $891 and 
$961 (p< 0.01) for these two groups respectively. Greater cost reductions were associ-
ated with improving EQ-5D scores at the lower end (< 0 to 0.3) and the mid-range (0.5 
to 0.7). cOnclusiOns: HRQoL is an important component of health care resource 
utilization. The findings suggest a significant relationship exists between health care 
costs and HRQoL data. The EQ-5D significantly predicts costs in asthma and asthma 
treatment, especially after adjusting non-random positive health care spending.
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Objectives: Chronic-Obstructive-Pulmonary-Disease (COPD) is a prevalent health 
condition mainly associated with smoking habit, which is considered the reason 
for higher health care resources utilization and related costs in the National health 
System. The aim of this study was to analyze and compare health care resource utili-
zation and costs according to smoking status in patients with COPD in clinical practice 
in Spain. MethOds: A retrospective cohort nested case-control study was designed. 
Cases were current smokers, while two controls (former smokers) per case matched 
for age, sex, duration of COPD, and burden of comorbidity (number of diagnosis and 
Charlson index) were included using data from medical records. Non-institutionalized 
COPD, both genders, 40 years of age and older, seen consecutively over a period of 4 
years before the index date and fulfilling eligibility criteria were considered eligible for 
analysis. Analysis used regression and general linear models with covariates to com-
pare direct and indirect costs and resource utilization. Results: A total of 930 COPD 
medical records were analyzed: 310 corresponding to cases (current smokers) and 630 
to controls (former smokers). Mean age was 69.4 years (84.6% male). COPD was more 
severe in cases; Odds ratio (OR)= 1.7 (95% CI 1.1;2.1), and higher percentage of current 
smokers had exacerbations [OR= 2,7 (2.0;3.8)], with 4.2 vs. 1.7 exacerbations per year, 
respectively, on average (p< 0.001). Smokers used more physicians visits both at pri-
mary care and specialized level, and emergency room as well. Drugs-based therapies 
were more common in current smokers COPD subjects. As a consequence, smokers 
had higher average annual health care costs; € 3,784 (1,888) vs. € 2,302 (2,451) in former 
smokers (p< 0.001). cOnclusiOns: COPD smoker patients had more exacerbations 
and higher severity of disease. Also, used more health care resources, particularly 
physicians visits and drugs-based therapies resulting in higher health care costs to 
the national health System.
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Objectives: In Finland a new Tobacco Act entered into force in October 2010 with 
the aim of limiting marketing and supply of tobacco products. The long-term objec-
tive of the Finnish government is to make Finland tobacco-free by 2040. Several 
work places and organizations have declared themselves non-smoking. The city 
of Mikkeli with a population of 55 000, has declared itself a non-smoking city and 
has established a non-smoking clinic in September 2011. Citizens contacting public 
health care and willing to quit smoking will be referred to the clinic. MethOds: 
Cross-sectional data was gathered 12 months after the establishment of the clinic. 
Costs related to investment and clinic’s resource utilization were estimated. A health 
care perspective was applied. Results: We studied 74 citizens, who had a least one 
visit during the first year since the establishment of the clinic. Of them 37% man-
aged to quit smoking. Investment costs related to planning and training of nurses 
were 168€ per quitter. Operational costs were 141-167€ per quitter. Total costs per 
quitter were 309-335€ . In the future investment costs per customer will decrease 
as investment costs were nonrecurring. cOnclusiOns: Our results were slightly 
better than what was achieved in an occupational health care non-smoking project 
in Finland (37% vs. 31%). In 2010 the average total costs of occupational health care 
were 340€ per employee in Finland. This is almost the same as the costs per quitter 
in this study. Cost of cigarettes is about 1800€ per average smoker in Finland. Health 
care costs related to lung cancer and stroke are about 18500€ per case during the 
first year. Pharmacological treatment costs about 200-400€ to quitter in average. 
Investing in smoking clinic is justified from economic and effectiveness point of 
views. The non-smoking clinic is still in operation.
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